Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with no LMWH (very low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in minor bleeding (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in catheter‐related infection (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
CVC‐related thrombosis ( · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in CVC‐related thrombosis ( compared with control (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in symptomatic CVC‐related thrombosis ( compared with control (low certainty).
1 finding from 1 review
Asymptomatic CVC‐related thrombosis ( · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in asymptomatic CVC‐related thrombosis ( compared with control (low certainty).
1 finding from 1 review
Major bleeding · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in major bleeding ( compared with control (low certainty).
1 finding from 1 review
Minor bleeding · children with a CVC
1 finding from 1 review
Death during study period · children with a CVC
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found